Baseline characteristics of participants in the Hypertension in the Very Elderly Trial (HYVET).
The Hypertension in the Very Elderly Trial (HYVET) is a randomized double-blind trial of active antihypertensive treatment (indapamide 1.5 mg sustained release +/-2-4 mg perindopril) vs placebo in participants over the age of 80 years with a systolic blood pressure (SBP) of 160-199 mmHg during a placebo run-in period plus a diastolic blood pressure (DBP) of<110 mmHg. The trial has completed with 3845 subjects randomized and we report the baseline characteristics. The participants were a healthy group. The numbers smoking, drinking alcohol and having previous cardiovascular events were low, and their hypertensive status was not usually associated with the metabolic syndrome; 1.0% of the whole group had a total cholesterol over 8.0 mmol/l, 1.1% a blood sugar over 11.1 mmol/l (irrespective of anti-diabetic treatment) and 1.7% a serum urate over 460 micromol/l (women) and 0.6% over 520 micromol/l (men). A serum creatinine over 150 micromol/l excluded participants from the trial. The gender differences and age comparisons were as expected but the women had higher average total and high-density-lipoprotein-cholesterol blood concentrations. Those with prior cardiovascular disease had an excess of the known cardiovascular risk factors. The baseline characteristics provide a basis for further understanding of the HYVET results, which have been published recently.
Bulpitt
Christopher John
CJ
Imperial College, Hammersmith Hospital, Care of the Elderly, London, UK. c.bulpitt@Imperial.ac.uk
Beckett
Nigel Stanley
NS
Peters
Ruth
R
Banya
Winston
W
Liu
Lisheng
L
Wang
Ji-Guang
JG
Stoyanovsky
Vassil
V
Dumitrascu
Dan
D
Nikitin
Yuri
Y
Staessen
Jan Albert
JA
Burch
Lisa
L
Fletcher
Astrid Elizabeth
AE
D000368:Aged; D000369:Aged, 80 and over / Q000502:physiology*; D000428:Alcohol Drinking / Q000453:epidemiology; D000886:Anthropometry; D001786:Blood Glucose / Q000032:analysis; D008076:Cholesterol, HDL / Q000097:blood; D015897:Comorbidity; D003404:Creatinine / Q000097:blood; D005260:Female; D006400:Hematocrit; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D006973:Hypertension / Q000097:blood / Q000188:drug therapy* / Q000453:epidemiology; D007190:Indapamide / Q000627:therapeutic use*; D008055:Lipids / Q000097:blood; D008297:Male; D018579:Patient Selection; D020913:Perindopril / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic / Q000706:statistics & numerical data*; D012907:Smoking / Q000453:epidemiology; D014508:Urea / Q000097:blood; D014527:Uric Acid / Q000097:blood
D001786:Blood Glucose; D008076:Cholesterol, HDL; D006454:Hemoglobins; D008055:Lipids; D014527:Uric Acid; D014508:Urea; D003404:Creatinine; D007190:Indapamide; D020913:Perindopril